PEG Interferon / Beijing Kawin  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
PEG Interferon / Beijing Kawin
NCT01908335: A Phase Ⅱ Dose-escalating Study of PEG-IFN-SA and Ribavirin in IFN Naive Patients With Chronic Hepatitis C

Completed
2
212
RoW
PEG-IFN-SA /RBV low dose, PEG-IFN-SA /RBV middle dose, PEG-IFN-SA /RBV high dose, Pegasys /RBV
Beijing Kawin Technology Share-Holding Co., Ltd.
Chronic Hepatitis C
08/13
07/14
NCT01605513: Safety Study of Recombinant Interferon Variant(PEG-IFN-SA) to Treat HCV Disease

Completed
1/2
80
RoW
interferon
The First Hospital of Jilin University
Hepatitis C Virus
12/13
12/13

Download Options